Zurück zur Übersicht
NCT00867048

Strategic Timing of Antiretroviral Treatment

Datenbasis: WHO (Import vom 03.05.2024)
Geändert: 13.03.2024, 01:00
Krankheitskategorie:

Health conditions (Datenquelle: WHO)

HIV Infection

Interventions (Datenquelle: WHO)

Drug: All licensed antiretroviral medications

Inclusion/Exclusion Criteria (Datenquelle: WHO)

Gender: All
Maximum age: N/A
Minimum age: 18 Years

INCLUSION CRITERIA:

- Signed informed consent

- HIV infection documented by a plasma HIV RNA viral load, rapid HIV test or any
licensed* ELISA test; and confirmed by another test using a different method including
but not limited to a rapid HIV test, Western Blot, HIV culture, HIV antigen, or HIV
pro-viral DNA at any time prior to study entry.

- Age greater than or equal to 18 years

- Karnofsky performance score greater than or equal to 80 (an indication that the
participant can perform normal activities)

- Perceived life expectancy of at least 6 months

- For women of child-bearing potential, willingness to use contraceptives as described
in the product information of the ART drugs they are prescribed

- Two CD4+ cell counts greater than 500 cells/mm(3) at least 2 weeks apart within 60
days before randomization

- The term licensed refers to an FDA-approved kit or, for sites located in
countries other than the United States, a kit that has been certified or licensed
by an oversight body within that country. Confirmation of the initial test result
must use a test method that is different than the one used for the initial
assessment.

EXCLUSION CRITERIA:

- Any previous use of ART or interleukin-2 (IL-2)

- Diagnosis of any clinical AIDS event before randomization (including esophageal
candidiasis and chronic Herpes simplex infection)

- Presence of HIV progression such as oral thrush, unexplained weight loss, or
unexplained fever

- Cardiovascular event (myocardial infarction, angioplasty, coronary-artery bypass
grafting, stroke) within 6 months before randomization

- Non-AIDS-defining cancer, excluding basal and squamous cell skin cancer, within 6
months before randomization

- Dialysis within 6 months before randomization

- Diagnosis of decompensated liver disease before randomization

- Current imprisonment, or compulsory detention (involuntary incarceration) for
treatment of a psychiatric or physical illness

- Current pregnancy or breastfeeding (a negative serum or urine pregnancy test is
required within 14 days before randomization for women of child-bearing potential)

Weitere Angaben zur Studie im WHO-Primärregister

https://clinicaltrials.gov/ct2/show/NCT00867048

Weitere Angaben zur Studie aus der Datenbank der WHO (ICTRP)

https://trialsearch.who.int/Trial2.aspx?TrialID=NCT00867048
Weitere Informationen zur Studie

Rekrutierungsstatus

Completed

Wissenschaftlicher Titel (Datenquelle: WHO)

Strategic Timing of AntiRetroviral Treatment

Studientyp (Datenquelle: WHO)

Interventional

Design der Studie (Datenquelle: WHO)

Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Phase (Datenquelle: WHO)

Phase 4

Primäre Endpunkte (Datenquelle: WHO)

Composite Endpoint of AIDS, Serious Non-AIDS Diagnoses, and All-cause Mortality

Sekundäre Endpunkte (Datenquelle: WHO)

AIDs or AIDs Related Death;Specific Non-AIDS Diagnoses;Death, All-cause Mortality;Quality of Life- Mean Change From Baseline in a Visual Analog Scale (VAS) for Perceived Current Health;Transmission Risk Behavior Outcome 1;Change in Neurocognitive Function (in a Subset of Participants);Large Artery Elasticity (in a Subset of Participants);Rate of Lung Function Decline (in a Subset of Participants) Among;Changes in Bone Mineral Density (in a Subset of Participants) Measure 1;Transmission Risk Behavior Outcome 2;Small Artery Elasticity (in a Subset of Participants);Rate of Lung Function Decline (in a Subset of Participants) Among Non-smokers;Changes in Bone Mineral Density (in a Subset of Participants) Measure 2

Kontakt für Auskünfte (Datenquelle: WHO)

Please refer to primary and secondary sponsors

Ergebnisse der Studie (Datenquelle: WHO)

Zusammenfassung der Ergebnisse

noch keine Angaben verfügbar

Link zu den Ergebnissen im Primärregister

https://clinicaltrials.gov/ct2/show/results/NCT00867048

Angaben zur Verfügbarkeit von individuellen Teilnehmerdaten

noch keine Angaben verfügbar

Studiendurchführungsorte

Durchführungsländer (Datenquelle: WHO)

Argentina, Australia, Austria, Belgium, Brazil, Chile, Czech Republic, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, India, Ireland, Israel, Italy, Luxembourg, Malaysia, Mali, Mexico, Morocco, Nigeria, Norway, Peru, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, Switzerland, Thailand, Uganda, United Kingdom, United States

Kontakt für weitere Auskünfte zur Studie

Kontakt für allgemeine Auskünfte (Datenquelle: WHO)

James D Neaton, PhD;Abdel Babiker, PhD;Jens Lundgren, MD, DMSc
University of Minnesota;Medical Research Council Clinical Trials Unit, London;Copenhagen HIV Programme

Kontakt für wissenschaftliche Auskünfte (Datenquelle: WHO)

James D Neaton, PhD;Abdel Babiker, PhD;Jens Lundgren, MD, DMSc
University of Minnesota;Medical Research Council Clinical Trials Unit, London;Copenhagen HIV Programme

Weitere Studienidentifikationsnummern

Secondary ID (Datenquelle: WHO)

U01AI068641
2008-006439-12
0603M83587
Zurück zur Übersicht